- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04309565
Transitions Clinic Network: Post Incarceration Addiction Treatment, Healthcare, and Social Support (TCN-PATHS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Purpose: The overall objective of this study is to assess whether the Transitions Clinic Network (TCN) program, which provides enhanced primary care and opioid use disorder (OUD) treatment for people recently released from incarceration, improves measures in the opioid treatment cascade compared to referral to standard primary care.
Participants: An anticipated 400 individuals currently receiving medications for OUD released from eight local jails (Durham, NC; Minneapolis, MN; Bronx, NY; Bridgeport and Niantic, CT; and Bayamón and Ponce, Puerto Rico)
Procedures: This is a hybrid type I effectiveness-implementation trial will randomize an anticipated 400 participants to one of two treatment conditions: TCN or standard primary care. People will complete the enrollment process while in jail (recruitment, screening, consent, baseline assessments, and randomization). Due to COVID-19 restrictions some jails are limiting researcher assess to people and some of our sites may enroll participants once they are released, this is referred to as a community enrollment. Post participants will meet with research assistants for a structured interview and urine toxicology screening at 1, 6, and 12 months, and a phone interview at months 3 and 9. 120 people will be selected to participate in Intensive Longitudinal Assessment (ILA) to access both the acceptability and appropriateness of the TCN intervention and the multi-level facilitators and barriers of OUD treatment engagement in the first 30 days following release from incarceration.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Emily Wang, MD
- Phone Number: 203-737-7624
- Email: emily.wang@yale.edu
Study Locations
-
-
-
San Juan, Puerto Rico
- Active, not recruiting
- University of Puerto Rico
-
-
-
-
Connecticut
-
New Haven, Connecticut, United States, 06511
- Recruiting
- Yale
-
Contact:
- Lisa Puglisi, MD
- Phone Number: 203-785-7411
- Email: lisa.puglisi@yale.edu
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- Recruiting
- Hennepin Healthcare
-
Contact:
- Tyler Winkelman, MD, MSc
-
-
New York
-
Bronx, New York, United States, 10467
- Active, not recruiting
- Albert Einstein College of Medicine
-
Rochester, New York, United States, 14627
- Withdrawn
- University of Rochester
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27510
- Recruiting
- UNC Chapel Hill
-
Contact:
- Lauren Brinkley-Rubenstein
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 years or older
- English and Spanish-speaking,
- Meeting current DSM-5 criteria for OUD
Exclusion Criteria:
- acutely psychotic, suicidal or homicidal,
- require prescription opioids for acute pain, chronic pain or palliative care without OUD,
- have a planned relocation that makes it unlikely they would be able to complete the study and follow-up assessments,
- have a primary care provider that they already have established care with in the community,
- women of child-bearing age will be excluded if they are pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard Primary Care
Those randomized to the standard primary care arm will be referred to primary care and community Opioid Treatment Program (OTP).
Participants may receive buprenorphine or Extended-release naltrexone (XR-NTX) through primary care or with a community addiction treatment provider.
|
Those randomized to the standard primary care arm will be referred to primary care and community Opioid Treatment Program (OTP).
Participants may receive buprenorphine or Extended-release naltrexone (XR-NTX) through primary care or with a community addiction treatment provider.
|
Experimental: Transitions Clinic Network Primary Care
Transitions Clinic Network (TCN)- participants in this arm will be referred to a TCN program for primary care and community Opioid Treatment Program (OTP).
All TCN programs have the ability to prescribe buprenorphine and Extended-release naltrexone (XR-NTX) and assist with referrals to methadone.
The primary features of the TCN include (1) primary care and onsite MOUD or referral to community treatment when indicated, (2) addressing social determinants of OUD and care coordination through a Community Health Worker (CHW), and (3) addressing the discrimination and stigma that exist based on incarceration.
|
Transitions Clinic Network (TCN)- participants in this arm will be referred to a TCN program for primary care and community Opioid Treatment Program (OTP).
All TCN programs have the ability to prescribe buprenorphine and Extended-release naltrexone (XR-NTX) and assist with referrals to methadone.
The primary features of the TCN include (1) primary care and onsite MOUD or referral to community treatment when indicated, (2) addressing social determinants of OUD and care coordination through a Community Health Worker (CHW), and (3) addressing the discrimination and stigma that exist based on incarceration.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Engagement in opioid use disorder (OUD) treatment
Time Frame: 30 days following jail release
|
The primary study outcome will be engagement in OUD treatment within 30 days of jail release, defined as treatment consistent with the American Society of Addiction Medicine's levels of care (1-4), which allows for a range of treatments and clinical settings consistent with patient's needs and preference (e.g., office-based providers of buprenorphine or naltrexone, OTPs, or intensive outpatient, inpatient, or residential treatments).
Patients do not need to be receiving methadone, buprenorphine, or naltrexone formulations (MOUD) to be considered engaged in OUD treatment.
This will be measured based on questions about engagement in OUD treatment.
These responses will be used to calculate a count of participants engaged in OUD treatment.
As appropriate, this information will be confirmed in the electronic health record or with the addiction treatment facilities after obtaining a signed release.
|
30 days following jail release
|
Retention in OUD treatment
Time Frame: 12 months following jail release
|
Retention in community OUD treatment will defined in accordance with the American Society of Addiction Medicine's levels of care (1-4), which allows for a range of treatments and clinical settings consistent with patient's needs and preference (e.g., office-based providers of buprenorphine or naltrexone, OTPs, or intensive outpatient, inpatient, or residential treatments).
Patients do not need to be receiving MOUD to be considered retained in OUD treatment.
Consistent with our prior research, this will be measured based on a Yes/No question about engagement in OUD treatment from the Treatment Services Review (TSR).
These responses will be used to calculate a count of participants engaged in OUD treatment.
As appropriate, this information will be confirmed in the electronic health record or with the addiction treatment facilities after obtaining a signed release.
Re-incarceration (and resumption of MOUD in jail) will not count as retained in community OUD treatment.
|
12 months following jail release
|
Retention on medication for OUD (MOUD)
Time Frame: 12 months following initial jail release
|
Retention on MOUD will be defined as receipt of any of the 3 FDA approved medications for OUD (methadone, buprenorphine, naltrexone) within 7 days of the index date (release from jail/interview date) regardless of what MOUD participants were on at baseline prior to release.
This measure will be collected by using self report and as appropriate, will confirm self-report in the electronic health record or with the addiction treatment facilities after obtaining a signed release.
|
12 months following initial jail release
|
Percent days of illicit opioid use
Time Frame: 12 months following initial jail release
|
Investigators will measure percent days of illicit opioid use during study time frames.
Investigators will measure this by asking the participant how many days during the study time frame have they used illicit opioids.
A urine toxicology that is positive for illicit opioids on testing will count as three days of using illicit opioids.
Using the data from the
|
12 months following initial jail release
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Retention in primary care
Time Frame: 12 months following jail release
|
Retention in primary care which is defined as 2 or more visits to primary care in twelve months.
Participants will be asked to self-report the number of visits and this data will be used to count the number of participants retained in primary care.
|
12 months following jail release
|
Overdose
Time Frame: 12 months following initial jail release
|
Participants will be asked about overdose events using self-report, when applicable, be supplemented by data from the electronic health record which will indicate visits to the emergency department and hospitalizations for overdose.
In at least four TCN program sites, investigators will have access to administrative payer data (Medicaid) where investigators will be able to examine time to overdose as a secondary outcome.
This data will be used to calculate a count of participants experiencing an overdose event
|
12 months following initial jail release
|
Time to Overdose
Time Frame: 12 months following initial jail release
|
In at least four of the six TCN program sites, investigators will have access to administrative payer data (Medicaid) where investigators will be able to examine time to overdose as a secondary outcome.
This data will be used to calculate time to overdose for each participant for each overdose event.
|
12 months following initial jail release
|
Death
Time Frame: 12 months following initial jail release
|
Participant death will be collected using the electronic health record.
In at least four of the six TCN program sites, investigators will have access to vital statistics data where survival analyses will be conducting with mortality as a secondary outcome.
|
12 months following initial jail release
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Emily Wang, MD, Yale University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2000027469
- 1UG1DA050072-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid Addiction
-
National Institute on Drug Abuse (NIDA)CompletedOpioid Abuse | Opioid Addiction | Stimulant Abuse | Stimulant AddictionUnited States
-
AphiosNot yet recruitingAddiction | Opioid Dependence | Opioid Withdrawal
-
Bubba NicholsonTampa General Hospital; Otrimed Clinical ResearchUnknownOpioid-Related Disorders | Opioid Dependence | Opioid Use | Opioid Abuse | Opioid-use Disorder | Opioid Addiction | Opioid Intoxication | Opioid Abuse, Continuous Use | Paternal Pheromone Deficiency | Opioid Abuse, Episodic
-
VA Office of Research and DevelopmentCompletedAlcohol Addiction | Opioid Addiction | Cocaine AddictionUnited States
-
Stanford UniversityNational Institute on Drug Abuse (NIDA); University of Wisconsin, Madison; Washington...Active, not recruitingAddiction, OpioidUnited States
-
Titan PharmaceuticalsCompleted
-
University of California, Los AngelesNot yet recruitingAddiction, Opioid
-
Jens KuhnUnknown
-
Beijing Pins Medical Co., LtdBeijing Tiantan HospitalUnknown
-
L.Molteni & C. dei F.lli Alitti-Soc. di Esercizio...Completed
Clinical Trials on Standard Primary Care
-
University of Maryland, BaltimoreCompleted
-
Sociedad Española de Neumología y Cirugía TorácicaInstituto de Salud Carlos IIICompletedSleep Apnea SyndromeSpain
-
University of TromsoThe Royal Norwegian Ministry of HealthActive, not recruiting
-
University of Cape TownKing's College London; University of KwaZuluCompletedDepression | HIV/AIDS | Chronic Diseases of LifestyleSouth Africa
-
Karolinska InstitutetRegion StockholmCompleted
-
Carlos III Health InstituteHealth Department of the Basque GovernmentCompleted
-
Norwegian University of Science and TechnologyCompleted
-
University of California, Los AngelesNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedPrediabetic StateUnited States
-
East Carolina UniversityThe Kate B. Reynolds Charitable TrustCompleted
-
Syracuse VA Medical CenterSyracuse UniversityCompleted